NIP
ALNY icon

Nicholas Investment Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nicholas Investment Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,526
Closed -$2.07M – 222
2024
Q3 		$2.07M Buy
+7,526
New +$1.96M 0.19% 165
2023
Q3 		– Sell
-90,351
Closed -$17.2M – 185
2023
Q2 		$17.2M Hold
90,351
– – 1.17% 29
2023
Q1 		$18.1M Buy
90,351
+37,467
+71% +$7.88M 1.38% 26
2022
Q4 		$12.6M Buy
52,884
+4,582
+9% +$977K 1.1% 36
2022
Q3 		$9.67M Buy
48,302
+1,222
+3% +$233K 0.9% 45
2022
Q2 		$6.87M Sell
47,080
-39,084
-45% -$5.54M 0.65% 52
2022
Q1 		$14.1M Buy
+86,164
New +$13.1M 1% 32
2016
Q1 		– Sell
-32,953
Closed -$3.1M – 304
2015
Q4 		$3.1M Buy
32,953
+11,568
+54% +$1.07M 0.21% 200
2015
Q3 		$1.72M Sell
21,385
-167
-0.8% -$18.6K 0.12% 261
2015
Q2 		$2.58M Sell
21,552
-26,821
-55% -$3.21M 0.17% 232
2015
Q1 		$5.05M Sell
48,373
-63,088
-57% -$6.39M 0.32% 117
2014
Q4 		$10.8M Buy
111,461
+115
+0.1% +$10.7K 0.68% 27
2014
Q3 		$8.7M Buy
111,346
+68,141
+158% +$4.4M 0.54% 38
2014
Q2 		$2.73M Buy
43,205
+818
+2% +$48.6K 0.16% 207
2014
Q1 		$2.85M Buy
+42,387
New +$3.28M 0.23% 147

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Nicholas Investment Partners's ALNY Position: Q4 2024 in Review

Nicholas Investment Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 7,526 shares — an estimated $2.07M sold.

Nicholas Investment Partners first reported a position in ALNY in Q1 2014 and held it in 15 quarters. The position peaked at $18.1M in Q1 2023. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Nicholas Investment Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 7,526 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $2.07M.
  • Nicholas Investment Partners first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 15 quarters.
  • Nicholas Investment Partners's Alnylam Pharmaceuticals position peaked at $18.1M in Q1 2023.
  • 594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Nicholas Investment Partners's 13F filing for Q4 2024, filed 14 Feb 2025.